These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 36769587)

  • 1. Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn's Disease: A Retrospective Real-World Analysis.
    Yao J; Zhang H; Su T; Peng X; Zhao J; Liu T; Wang W; Hu P; Zhi M; Zhang M
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
    Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
    [No Abstract]   [Full Text] [Related]  

  • 3. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.
    Zhu M; Xu X; Feng Q; Cui Z; Wang T; Yan Y; Ran Z
    Dig Dis Sci; 2021 May; 66(5):1658-1668. PubMed ID: 32524415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.
    Newman KL; Johnson LA; Stidham RW; Higgins PDR
    Therap Adv Gastroenterol; 2023; 16():17562848221148254. PubMed ID: 36895282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn's Disease.
    Swaroop S; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Arora U; Goyal A; Kandasamy D; Sharma R; Kabilan K; Kedia S; Dash NR; Ahuja V
    Stem Cell Res Ther; 2024 May; 15(1):140. PubMed ID: 38745184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial.
    Panés J; Bouma G; Ferrante M; Kucharzik T; Nachury M; de la Portilla de Juan F; Reinisch W; Selvaggi F; Tschmelitsch J; Brett NR; Ladouceur M; Binek M; Hantsbarger G; Campbell-Hill S; Karki C; Buskens C
    Inflamm Bowel Dis; 2022 Nov; 28(11):1737-1745. PubMed ID: 35099555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
    Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
    BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis.
    Godoy Brewer GM; Salem G; Afzal MA; Limketkai BN; Haq Z; Tajamal M; Melia J; Lazarev M; Selaru FM; Parian AM
    BMJ Open Gastroenterol; 2021 Dec; 8(1):. PubMed ID: 34920992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
    Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
    Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future.
    Caron B; D'Amico F; Danese S; Peyrin-Biroulet L
    J Crohns Colitis; 2021 Aug; 15(8):1387-1398. PubMed ID: 33550374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn's disease.
    van Rijn KL; Lansdorp CA; Tielbeek JAW; Nio CY; Buskens CJ; D'Haens GRAM; Löwenberg M; Stoker J
    Clin Imaging; 2020 Feb; 59(2):179-187. PubMed ID: 31821976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which magnetic resonance imaging feature is associated with treatment response in perianal fistulizing Crohn's disease?
    Richard N; Derinck A; Bridoux V; Charpentier C; Savoye Collet C; Savoye G
    Abdom Radiol (NY); 2024 Aug; 49(8):2913-2920. PubMed ID: 38512515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature.
    Attauabi M; Burisch J; Seidelin JB
    Scand J Gastroenterol; 2021 Jan; 56(1):53-58. PubMed ID: 33264569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life effectiveness of allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulizing refractory Crohn's disease.
    Alonso-Gomez M; Charlois AL; Cotte E; Gay C; Danion P; Malezieux E; Altwegg R; Boschetti G; Nancey S
    Clin Res Hepatol Gastroenterol; 2024 Nov; 48(9):102473. PubMed ID: 39349101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease.
    Rasul I; Wilson SR; MacRae H; Irwin S; Greenberg GR
    Am J Gastroenterol; 2004 Jan; 99(1):82-8. PubMed ID: 14687146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn's Disease Patients.
    van Rijn KL; Meima-van Praag EM; Bossuyt PM; D'Haens GR; Gecse KB; Horsthuis K; Snijder HJ; Tielbeek JAW; Buskens CJ; Stoker J
    J Crohns Colitis; 2022 Jun; 16(5):708-716. PubMed ID: 34644395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for Standardizing MRI-based Evaluation of Perianal Fistulizing Disease Activity in Pediatric Crohn's Disease Clinical Trials.
    Crowley E; Ma C; Guizzetti L; Zou G; Lewindon PJ; Gee MS; Hyams JS; Rosen MJ; von Allmen D; de Buck van Overstraeten A; Shackelton LM; Remillard J; Schleicher L; Dillman JR; Rimola J; Taylor SA; Fletcher JG; Church PC; Feagan BG; Griffiths AM; Jairath V; Greer MC
    Inflamm Bowel Dis; 2024 Mar; 30(3):357-369. PubMed ID: 37524088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the effectiveness of infliximab on perianal fistulizing Crohn's disease by magnetic resonance imaging.
    Yan X; Zhu M; Feng Q; Yan Y; Peng J; Xu X; Xu A; Ran Z
    Gastroenterol Rep (Oxf); 2019 Feb; 7(1):50-56. PubMed ID: 30792866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.